Ondansetron Administration in Adults
Ondansetron should be administered as 8 mg orally or intravenously for most indications, with the specific dose, route, and timing dependent on the clinical context—whether for chemotherapy-induced nausea/vomiting (CINV), radiation-induced nausea/vomiting (RINV), or postoperative nausea/vomiting (PONV).
Chemotherapy-Induced Nausea and Vomiting (CINV)
Highly Emetogenic Chemotherapy
- Administer 16-24 mg PO once OR 8-16 mg IV once on Day 1, given 30 minutes before chemotherapy 1
- This is part of a multi-drug regimen that includes an NK1 antagonist and dexamethasone 1
- The FDA label supports a single 24 mg oral dose for highly emetogenic chemotherapy, administered 30 minutes prior to treatment 2
Moderately Emetogenic Chemotherapy
- Give 16-24 mg PO once OR 8-16 mg IV once on Day 1, 30 minutes before chemotherapy 1
- Continue with 8 mg PO twice daily on Days 2-3 after chemotherapy completion 2
- The first dose should be given 30 minutes before chemotherapy starts, with a subsequent dose 8 hours later 2
Important caveat: The 8 mg three-times-daily regimen is NOT recommended despite being studied, as twice-daily dosing is equally effective 2
Radiation-Induced Nausea and Vomiting (RINV)
High-Risk Radiation (Total Body Irradiation)
- Administer 8 mg PO or 8 mg IV once to twice daily on radiation days 3
- Give the first dose before radiation therapy 3
- Continue once daily on non-radiation days if radiation is not planned 3
Moderate-Risk Radiation (Upper Abdomen, Craniospinal)
- Give 8 mg PO or 8 mg IV once daily before radiation therapy 3
- Continue once daily on the day after each radiation treatment if no radiation is scheduled 3
Low-Risk Radiation (Brain, Head/Neck, Thorax, Pelvis)
- Administer 8 mg PO or 8 mg IV once daily before radiation therapy 3
- Use as prophylactic therapy on radiation days 3
Postoperative Nausea and Vomiting (PONV)
Timing Considerations
- Administer 4 mg IV at the end of surgery rather than before induction of anesthesia 4
- This timing is more effective in reducing the need for rescue antiemetics (36% vs 64% with placebo) 4
- When given before induction, ondansetron does not significantly reduce PONV incidence compared to end-of-surgery administration 4
Dosing
- Standard dose is 4 mg IV for PONV prophylaxis 5
- The FDA label supports 16 mg PO as a single dose given 1 hour before anesthesia induction, though end-of-surgery timing may be preferable based on clinical evidence 2, 4
Route-Specific Considerations
Intravenous Administration
- Dose: 0.15 mg/kg IV (maximum 8-16 mg depending on indication) 3, 1
- IV administration produces the largest improvements in nausea scores (mean decrease 4.4 on 10-point scale) 6
- Safe and effective in prehospital settings when administered by paramedics 6
Oral Administration
- Standard dose: 8 mg PO for most indications 3, 1
- Oral dissolving tablets (ODT): 8 mg, effective alternative to IV/IM routes 3, 6
- Oral soluble film: 8 mg, another convenient formulation 3
- Oral route produces mean nausea score decrease of 3.3 on 10-point scale 6
Intramuscular Administration
- Rarely used but effective: Mean nausea score improvement of 3.6 6
- Can be considered when IV access is unavailable 6
Special Populations
Hepatic Impairment
- Maximum dose: 8 mg daily in patients with severe hepatic impairment (Child-Pugh ≥10) 2
- Clearance is reduced 2-3 fold with increased half-life to 20 hours 2
Renal Impairment
- No dose adjustment required as renal clearance represents only 5% of total clearance 2
- Mean plasma clearance reduced by 50% in severe renal impairment, but this is not clinically significant 2
Safety Profile
- Adverse events are rare: In a large prehospital study of 2,071 patients, only 8 adverse events occurred (4 mild hypotension, 2 itching/rash, 1 hypertension, 1 brief SVT) 6
- QT prolongation: Be aware of this risk, particularly with higher doses 7
- Pregnancy: Ondansetron use in hyperemesis gravidarum is associated with decreased spontaneous abortion risk (HR 0.82) and no increased stillbirth risk 7